


LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

11767-032-999

APPLICATION NO.

09/623,543

APPLICANT

Bridon et al.

FILING DATE

September 5, 2000

ART UNIT

1642

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	5,424,286	06/13/95	Eng	
	A02	60/037,412	02/05/97	Drucker	
	A03	60/103,498	10/08/98	Coolidge <i>et al.</i>	
	A04	60/132,018	4/30/99	Prickett <i>et al.</i>	
	A05	6,284,725 B1	09/04/01	Coolidge <i>et al.</i>	
	A06	6,451,974 B1	09/17/02	Hansen	
	A07	6,723,530 B1	04/20/04	Drucker	
	A08	6,767,887 B1	07/27/04	Hoffman <i>et al.</i>	
	A09	60/152,681	09/07/99	Ezrin <i>et al.</i>	
	A10	2003/0170250	09/11/03	Ezrin <i>et al.</i>	
	A11	2004/0156859	08/12/04	Ezrin <i>et al.</i>	
	A12	2004/0266673	12/30/04	Bakis <i>et al.</i>	
	A13	2005/0065075	03/24/05	Erickson <i>et al.</i>	
	A14	2005/0070475	03/31/05	Bridon <i>et al.</i>	
	A15	2005/0176641	08/11/05	Bakis <i>et al.</i>	
	A16	2005/0176643	08/11/05	Bridon <i>et al.</i>	
	A17	2006/0058235	03/16/06	Bridon <i>et al.</i>	
	A18	2006/0135426	06/22/06	Bridon <i>et al.</i>	
	A19	2006/0135428	06/22/06	Bridon <i>et al.</i>	
	A20	2006/0217304	09/28/06	Bridon <i>et al.</i>	
	A21	2006/0241019	10/26/06	Bridon <i>et al.</i>	
	A22	2007/0207958	09/06/07	Bridon <i>et al.</i>	
	A23	2007/0269863	11/22/07	Bridon <i>et al.</i>	
	A24	5,840,733	11/24/98	Krantz <i>et al.</i>	
	A25	5,843,440	12/01/98	Pouletty <i>et al.</i>	
	A26	5,942,620	08/24/99	Krantz <i>et al.</i>	
	A27	6,087,375	08/11/00	Bridon <i>et al.</i>	
	A28	6,103,233	08/15/00	Pouletty <i>et al.</i>	
	A29	6,277,583	08/21/01	Krantz <i>et al.</i>	

NYI-4069369v1

EXAMINER
DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 11767-032-999	APPLICATION NO. 09/623,543
	APPLICANT Bridon et al.	
	FILING DATE September 5, 2000	ART UNIT 1642

U.S. PATENT DOCUMENTS					
*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A30	6,277,863	08/21/01	Krantz <i>et al.</i>	
	A31	6,403,324	06/11/02	Krantz <i>et al.</i>	
	A32	6,437,092	08/20/02	Ezrin <i>et al.</i>	
	A33	6,440,417	08/27/02	Thibaudeau <i>et al.</i>	
	A34	6,451,974	09/17/02	Hansen	
	A35	6,602,981	08/05/03	Ezrin <i>et al.</i>	
	A36	6,610,825	08/26/03	Ezrin <i>et al.</i>	
	A37	6,706,892	03/16/04	Ezrin <i>et al.</i>	
	A38	6,887,470	05/03/05	Bridon <i>et al.</i>	
	A39	7,090,851	08/15/06	Bridon <i>et al.</i>	
	A40	7,112,567	09/26/06	Bridon <i>et al.</i>	
	A41	7,166,695	01/23/07	Krantz <i>et al.</i>	
	A42	7,256,253	08/14/07	Bridon <i>et al.</i>	
	A43	7,268,113	09/11/07	Bridon <i>et al.</i>	
	A44	7,307,148	12/01/07	Bousquet Gagnon <i>et al.</i>	
	A45	6,107,489	08/22/00	Krantz <i>et al.</i>	
	A46	6,329,336	12/11/01	Bridon <i>et al.</i>	
	A47	6,500,918	12/31/02	Ezrin <i>et al.</i>	
	A48	2004/0127398	07/01/04	Bridon <i>et al.</i>	
	A49	2004/0138100	07/15/04	Bridon <i>et al.</i>	
	A50	09/424,571	11/22/99	Ezrin <i>et al.</i>	
	A51	4,462,941	07/31/1984	Lee <i>et al.</i>	
	A52	5,493,007	02/20/1996	Burnier <i>et al.</i>	
	A53	5,580,853	12/03/1996	Sytkowski	
	A54	5,654,276	08/05/1997	Barrett <i>et al.</i>	
	A55	5,843,440	12/01/1998	Pouletty <i>et al.</i>	
	A56	6,849,714	02/01/2005	Bridon <i>et al.</i>	
	A57	6,514,500	02/04/2003	Bridon <i>et al.</i>	
	A58	6,593,295	07/15/2003	Bridon <i>et al.</i>	

NYI-4069369v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 11767-032-999	APPLICATION NO. 09/623,543
	APPLICANT Bridon et al.	
	FILING DATE September 5, 2000	ART UNIT 1642

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear /
	A59	6,821,949	11/23/2004	Bridon <i>et al.</i>	
	A60	6,329,336	12/11/2001	Bridon <i>et al.</i>	
	A61	6,887,849	05/03/2005	Bridon et al.	

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	WO 00/69902	05/17/00	ConjuChem, Inc.		
	B02	WO 00/69911	11/23/2000	ConjuChem, Inc.		
	B03	WO 01/017568	09/07/00	ConjuChem, Inc.		
	B04	WO 01/017614	09/07/00	ConjuChem, Inc.		
	B05	WO 02/062844	01/02/02	ConjuChem, Inc.		
	B06	WO 02/066511	02/15/02	ConjuChem, Inc.		
	B07	WO 02/096935	05/31/02	ConjuChem, Inc.		
	B08	WO 04/011498	07/29/03	ConjuChem, Inc.		
	B09	WO 05/012346	07/26/04	ConjuChem, Inc.		
	B10	WO 05/103087	04/22/05	ConjuChem Biotechnologies Inc.		
	B11	WO 05/108418	06/15/05	ConjuChem Biotechnologies Inc.		
	B12	WO 07/053946	11/09/06	ConjuChem Biotechnologies Inc.		
	B13	WO 07/071068	12/22/06	ConjuChem Biotechnologies Inc.		
	B14	WO 91/08220	06/13/91	Houen Gunnar		
	B15	WO 97/25074	01/07/97	Redcell Canada, Inc.		
	B16	WO 97/29372	01/07/97	Redcell Inc.		
	B17	WO 97/46584	12/11/97	Boehringer Mannheim GmbH		
	B18	WO 98/00171	06/30/97	ConjuChem, Inc.		
	B19	WO 98/05351	02/12/98	Amylin Pharmaceuticals, Inc.		
	B20	WO 98/11437	09/16/97	ConjuChem, Inc.		
	B21	WO 99/07404	02/18/99	Amylin Pharmaceuticals, Inc.		
	B22	WO 99/24071	05/20/99	ConjuChem, Inc.		

NYI-4069369v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 11767-032-999	APPLICATION NO. 09/623,543
	APPLICANT Bridon et al.	
	FILING DATE September 5, 2000	ART UNIT 1642

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date mm/dd/yy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B23	WO 99/24076	11/06/98	ConjuChem, Inc.		
	B24	WO 99/24462	05/20/1999	ConjuChem, Inc.		
	B25	WO 99/25727	05/27/99	Amylin Pharmaceuticals, Inc.		
	B26	WO 99/25728	05/27/99	Amylin Pharmaceuticals, Inc.		
	B27	WO 99/46283	09/16/99	Zealand Pharmaceuticals A/S		

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	Alberts <i>et al.</i> , 1994, <i>Molecular Biology of the Cell, Third Edition</i> , New York: Garland Publishing, page G19.	
	C02	Barragán <i>et al.</i> , 1996, "Interactions of Exendin(9-39) with the Effects of Glucagon-Like Peptide-1-(7-36) Amide and of Exendin-4 on Arterial Blood Pressure and Heart Rate in Rats," 67:63-68.	
	C03	Binder <i>et al.</i> , 1984, "Insulin Pharmacokinetics," <i>Diabetes Care</i> 7:188-199.	
	C04	Breton <i>et al.</i> , 1995, "Prolonged Half-Life in the Circulation of a Chemical Conjugate Between a Pro-Urokinase Derivative and Human Serum Albumin," <i>Eur. J. Biochem.</i> 231:563-569.	
	C05	<i>Catalog, Shearwater Polymers, Inc., Functionalized Biocompatible Polymers for Research, Polyethylene Glycol Derivatives</i> , 1993.	
	C06	Cooper, 1997, <i>The Cell A Molecular Approach</i> , ASM Press (Washington, DC), Sinauer Associates, Inc. (Sunderland, MA), 296-298, 648.	
	C07	Edwards <i>et al.</i> , 1999 (December), "Glucagon-Like Peptide 1 Has a Physiological Role in the Control of Postprandial Glucose in Humans," <i>Diabetes</i> 48: 86-93.	
	C08	Eng <i>et al.</i> , 1990, "Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from <i>Heloderma horridum</i> Venom," <i>J. Biol. Chem.</i> 265:20259-20262.	
	C09	Eng <i>et al.</i> , 1992, "Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from <i>Heloderma suspectum</i> Venom," <i>J. Biol. Chem.</i> 267:7402-7405.	
	C10	Gennaro, ed., 1995, <i>Remington: The Science and Practice of Pharmacy</i> , 19 th Edition, 898, 931-94.	
	C11	Göke <i>et al.</i> , 1989, "Characterization of the Receptor for Glucagon-like-peptide-1(7-36)amide on Plasma Membranes from Rat Insulinoma-derived Cells by Covalent Cross-Linking," <i>J. Mol. Endocrinol.</i> 2:93-98.	
	C12	Göke <i>et al.</i> , 1992, "Solubilization of Active GLP-1 (7-36)amide Receptors From RINm5F Plasma Membranes," <i>FEBS Lett.</i> 300:232-236.	
	C13	Göke <i>et al.</i> , 1993, "Exendin-4 is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β -Cells," <i>J. Biol. Chem.</i> 268(26):19650-19655.	
	C14	Göke <i>et al.</i> , 1995, "Distribution of GLP-1 Binding Sites in the Rat Brain: Evidence that Exendin-4 is a Ligand of Brain GLP-1 Binding Sites," <i>Eur. J. Neurosci.</i> 7:2294-2300.	
	C15	Gombotz and Pettit, 1995, "Biodegradable Polymers for Protein and Peptide Drug Delivery," <i>Bioconjugate Chem.</i> 6:332-351.	
	C16	Grand, 1989, "Acylation of Viral and Eukaryotic Proteins," <i>Biochem J.</i> 258:625-638.	

NYI-4069369v1

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

11767-032-999

APPLICATION NO.

09/623,543

APPLICANT

Bridon et al.

FILING DATE

September 5, 2000

ART UNIT

1642

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C17	Grieg et al., 1999 (January), "Once Daily Injection of Exendin-4 to Diabetic Mice Achieves Long-Term Beneficial Effects of Blood Glucose Concentrations," <i>Diabetologia</i> 42:45-50.	
	C18	Harlow & Lane, 1988, <i>Antibodies: A Laboratory Manual</i> , pp. 101, 129.	
	C19	Hoshino et al., 1984, "Primary Structure of Helodermin, a VIP-Secretin-Like Peptide Isolated from Gila Monster Venom," <i>FEBS Lett.</i> 178:233-239	
	C20	Isoai et al., 1993, "A Potent Anti-Metastatic Activity of Tumor Invasion-Inhibiting Factor-2 and Albumin Conjugate," <i>Biochem. Biophys. Res. Comm.</i> 192:7-14.	
	C21	Lewis, 1997, <i>Hawley's Condensed Chemical Dictionary, 13th Edition</i> , John Wiley & Sons, Inc. (New York), 487, 815.	
	C22	Mattson et al., 1993, "A Practical Approach to Crosslinking," <i>Mol. Biol. Reports</i> 17:167-183.	
	C23	Petrella et al., 1999 (May), "Development and Validation of an Immunoradiometric Assay (IRMA) for the Quantitation of Exendin-4 in Plasma and Its Application to Preclinical Toxicity and Phase I Clinical Evaluations," <i>Diabetes</i> 48:A425.	
	C24	Poznansky & Juliano, 1984, "Biological Approaches to the Controlled Delivery of Drugs: A Critical Review," <i>Pharmacological Reviews</i> 36:277-335.	
	C25	Raufman, 1996, "Bioactive Peptides from Lizard Venoms," <i>Regulatory Peptides</i> 61:1-18.	
	C26	Richter et al., 1991, "Characterization of Glucagon-Like Peptide-I(7-36)amide Receptors of Rat Lung Membranes by Covalent Cross-Linking," <i>FEBS Lett.</i> 280:247-250	
	C27	Robberecht et al., 1985, "Immunoreactive Helodermin-like Peptides in Rat: A New Class of Mammalian Neuropeptides Related to Secretin and VIP" <i>Biochem Biophys. Res. Comm.</i> 130: 333-342.	
	C28	Schirra et al., 1998, "Exendin(9-39)amide is an Antagonist of Glucagon-Like Peptide-I(7-36)amide in Humans," <i>J. Clin. Invest.</i> 101:1421-1430.	
	C29	Schmidtler et al., 1994, "Rat Parietal Cell Receptors for GLP-1(7-36) Amide: Northern Blot, Cross-Linking, and Radioligand Binding," <i>Am. J. Physiol.</i> 267:G423-432.	
	C30	Syed et al., 1997, "Potent Antithrombin Activity and Delayed Clearance From the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin," <i>Blood</i> 89:3243-3252.	
	C31	Vandermeers et al., 1984, "Purification of a Novel Pancreatic Secretory Factor (PSF) and a Novel Peptide with VIP- and Secretin-like Properties (Helodermin) from Gila Monster Venom," <i>FEBS Lett.</i> 166:273-276.	
	C32	Vandermeers et al., 1987, "Chemical, Immunological and Biological Properties of Peptides Like Vasoactive-Intestinal-Peptide and Peptide-Histidine-Isoleucinamide Extracted from the Venom of Two Lizards (<i>Heloderma horridum</i> and <i>Heloderma suspectum</i>)," <i>Eur. J. Biochem.</i> 164:321-327.	
	C33	Yeh et al., 1992, "Design of Yeast-Secreted Albumin derivatives for Human Therapy: Biological and Antiviral Properties of a Serum Albumin-CD4 Genetic Conjugate," <i>Proc. Natl. Acad. Sci. USA</i> 89:1904-1908.	
	C34	Meloun et al., 1975, "Complete Amino Acid Sequence of Human Serum Albumin," <i>FEBS Letters</i> 58, 134-137	
	C35	Davis et al., 1991, "Reduction of Immunogenicity and extension of circulating half-life of peptides and proteins," <i>Peptide and Protein Drug Delivery</i> , Marcel Dekker, Inc., NY, NY, 831-864	
	C36	Paige et al., 1995, "Prolonged circulation of recombinant human granulocyte-colony stimulating factor by covalent linkage to albumin through a heterobifunctional polyethylene glycol," <i>Pharm. Research.</i> , Vol. 12(12), 1883-1888	
	C37	Poznansky, 1983, "Enzyme-protein conjugates: new possibilities for enzyme therapy," <i>Pharm. Ther.</i> , Vol. 21, pp. 53-76	
	C38	Poznansky et al., 1988, "Growth hormone-albumin conjugates reduced renal toxicity and altered plasma clearance," <i>Federation of European Biochemical Societies</i> , Vol. 239(1), pp 18-22	

NYI-4069369v1

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.